Literature DB >> 34475348

The interaction of hypertension and homocysteine increases the risk of mortality among middle-aged and older population in the United States.

Wenyan Zhao1, Faliang Gao2, Laidi Lv3, Xi Chen1.   

Abstract

OBJECTIVES: To investigate the interaction of hypertension and total plasma homocysteine (tHcy) levels on risk of all-cause and cardiovascular disease (CVD) mortality among middle-aged and older population.
METHODS: This observational cohort study analyzed data from the National Health and Nutrition Examination Survey database (1999-2002 survey cycle). A generalized additive model (GAM) based on Cox proportional hazards models was applied to estimate the relationship of tHcy level with all-cause and CVD mortality. Stratification analyses by sex and renal function were performed.
RESULTS: Among 5724 individuals aged 40-85, 704 (12.3%) died, with 339 CVD deaths after a median follow-up period of 5.58 years. Mean age was 60.7 ± 13.4 years (49.6% men). In the fully adjusted model, we found that per 1 μmol/l increment of plasma tHcy was associated with 8% increased risk of all-cause mortality and 7% increased risk of CVD mortality in hypertensive participants. The adjusted hazard ratio (95% CIs) for all-cause and CVD mortality were 1.08 (1.06-1.10) and 1.07 (1.04-1.10), respectively. There were pronounced interactive effects between hypertension and tHcy levels on risk of all-cause mortality (P for interaction = 0.031).
CONCLUSION: Hypertension and tHcy levels can interactively affect the risk of all-cause mortality among middle-aged and older population. Conceivably, hypertension may further enhance the ability of elevated tHcy to provoke the risk of all-cause mortality.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34475348     DOI: 10.1097/HJH.0000000000003002

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Resveratrol: A new approach to ameliorate hyperhomocysteinaemia-induced renal dysfunction.

Authors:  Xuan Zhao; Qing-Chen Hui; Rui Xu; Ning Gao; Ping Cao
Journal:  Exp Ther Med       Date:  2022-06-10       Impact factor: 2.751

2.  Homocysteine Solution-Induced Response in Aerosol Jet Printed OECTs by Means of Gold and Platinum Gate Electrodes.

Authors:  Pasquale D'Angelo; Mario Barra; Patrizia Lombari; Annapaola Coppola; Davide Vurro; Giuseppe Tarabella; Simone Luigi Marasso; Margherita Borriello; Federico Chianese; Alessandra F Perna; Antonio Cassinese; Diego Ingrosso
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

3.  Development and validation of a novel nomogram to predict overall survival of patients with moderate to severe chronic kidney disease.

Authors:  Ning Li; Guowei Zhou; Yawei Zheng; Enchao Zhou; Weiming He; Wei Sun; Lu Zhang
Journal:  Ren Fail       Date:  2022-01-23       Impact factor: 2.606

4.  Associations of Serum and Red Blood Cell Folate With All-Cause and Cardiovascular Mortality Among Hypertensive Patients With Elevated Homocysteine.

Authors:  Long Zhou; Hui Huang; Xiaoxiao Wen; Yu Chen; Jie Liao; Fuli Chen; Liancheng Zhao; Mingjiang Liu; Jianhong Tao; Gang Li
Journal:  Front Nutr       Date:  2022-02-25

5.  New Evidence for Homocysteine Lowering for Management of Treatment-Resistant Hypertension.

Authors:  Merrill F Elias; Craig J Brown
Journal:  Am J Hypertens       Date:  2022-04-02       Impact factor: 2.689

6.  Elevated Expression of JMJD5 Protein Due to Decreased miR-3656 Levels Contributes to Cancer Stem Cell-Like Phenotypes under Overexpression of Cancer Upregulated Gene 2.

Authors:  Natpaphan Yawut; Il-Rae Cho; Phatcharaporn Budluang; Sirichat Kaowinn; Chutima Kaewpiboon; Byeoleun Jeon; Sang-Woo Kim; Ho Young Kang; Min-Kyung Kang; Sang Seok Koh; Young-Hwa Chung
Journal:  Biomolecules       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.